Paxalisib for newly diagnosed glioblastoma after standard treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called paxalisib in people with a newly diagnosed aggressive brain tumor (glioblastoma) who have just finished standard radiation and chemotherapy. The goal is to see if adding paxalisib can help prevent the tumor from coming back by targeting a specific pathway in the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called glioblastoma (IDH-wildtype, Grade 4).
- You must have finished standard radiation and chemotherapy (Stupp protocol) within the last 6 weeks, and your tumor must not have grown after that treatment.
- You must be 16 years old or older.
- You must be able to take care of yourself (fully active or able to do light work).
- Your blood counts and organ function (kidney, liver, etc.) must be within certain ranges, and you must not have uncontrolled diabetes, heart problems, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This Phase 2 study tests paxalisib to shrink or control primary CNS lymphoma that has come back or did not respond to prior treatment. It may help by blocking specific cell-growth signals that can drive this lymphoma.
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
This trial tests a cancer-immunotherapy medicine (an anti–PD-1 antibody, similar to pembrolizumab) combined with precisely targeted radiation to treat glioblastoma that has come back or progressed. It may help your immune system recognize and attack the tumor while the radiation targets the cancer.
This trial tests a combination of two drugs (niraparib and temozolomide) for people with glioblastoma or other gliomas that have come back after standard treatment. Niraparib is a type of drug that may help stop cancer cells from repairing themselves, making temozolomide work better.
Hear when a new Malignant Primary Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.